What is Scala Biodesign?
Scala Biodesign is a biotechnology firm specializing in advanced computational platforms for the design and optimization of proteins. Their technology leverages artificial intelligence, evolutionary data, and structural modeling to enhance the stability, activity, and manufacturability of biologics such as enzymes and antibodies. Positioned within the burgeoning field of AI-driven protein engineering, Scala Biodesign aims to accelerate bioproduct development and reduce experimental complexities, offering a more efficient pathway for creating pharmaceuticals, chemicals, and sustainable industrial solutions.
How much funding has Scala Biodesign raised?
Scala Biodesign has raised a total of $21.5M across 2 funding rounds:
Angel/Seed
$5.5M
Series A
$16M
Angel/Seed (2023): $5.5M with participation from TLV Partners
Series A (2026): $16M led by TLV Partners, Deep Insight, Grove Ventures Ltd, and Israel Innovation Authority
Key Investors in Scala Biodesign
TLV Partners
TLV Partners is an Israeli venture capital firm focused on early-stage startups, backing innovative entrepreneurs across sectors like AI and healthcare. They aim to accelerate technological advancements through strategic investments.
Deep Insight
Deep Insight Innovations is an Israeli fund dedicated to deep tech opportunities, investing in areas such as semiconductors, bio convergence, and AI. They aim to promote pioneering solutions across various high-tech fields.
Grove Ventures Ltd
Grove Ventures is an early-stage venture capital firm managing over half-a-billion dollars, partnering with Israeli entrepreneurs to build future-focused companies. They are headquartered in Tel Aviv-Yafo, Israel.
What's next for Scala Biodesign?
The recent major strategic investment signals a pivotal growth phase for Scala Biodesign. This capital infusion is expected to fuel further research and development, potentially expanding the company's computational capabilities and market reach. The company's focus on AI-driven protein engineering positions it to capitalize on the increasing demand for novel biologics across various industries, suggesting a trajectory towards scaling its operations and solidifying its market leadership in advanced biomolecular design.
See full Scala Biodesign company page
